Prognostic Significance of Metallothionein in Human Gastrointestinal Cancer 1

PURPOSE Metallothionein (MT) is a small protein with a high affinity for divalent heavy metal ions. This metalloproteinis involved in many (patho)physiological processes, like metal homeostasis and detoxification, cell proliferation, apoptosis, therapy resistance, and protection against oxidative damage. Alterations in the immunohistochemical expression of MT have been reported for various human tumors, and a high expression has been found to be associated with a poor clinical outcome. We showed previously that gastrointestinal cancer is accompanied by a decrease in MT expression, but the most malignant phenotypes had the highest MT levels. The purpose of the present study was to assess the clinical relevance of MT in gastrointestinal cancer. EXPERIMENTAL DESIGN In this study, we determined the MT levels, by radioimmunoassay, in intestinal tissue of 251 patients with colorectal cancer and 81 patients with gastric cancer and assessed the relation with the overall survival of these patients. RESULTS More than 74% of the carcinomas were found to have a lower MT level than their corresponding normal mucosa. In colorectal cancer patients, but not in gastric cancer patients, a high MT level in both the carcinomas and normal mucosa was, however, significantly associated with a poor overall survival, independently from clinicopathological features. CONCLUSIONS Overexpression of MT in intestinal tissue of colorectal cancer patients is a prognostic marker for a poor overall survival. In gastric cancer, however, MT expression in the gastric mucosa is not of prognostic significance. This observation emphasizes the clinical relevance of this multifunctional metalloprotein in colorectal carcinogenesis and therapy.

[1]  H. Verspaget,et al.  Development of a radioimmunoassay for human metallothionein. , 1990, Journal of immunological methods.

[2]  A. Abdel-Mageed,et al.  Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. , 1997, Cancer gene therapy.

[3]  M Sato,et al.  Oxygen free radicals and metallothionein. , 1993, Free radical biology & medicine.

[4]  H. Lohrer,et al.  Overexpression of metallothionein in CHO cells and its effect on cell killing by ionizing radiation and alkylating agents. , 1989, Carcinogenesis.

[5]  P. C. Huang,et al.  National Cancer Institute workshop on the possible roles of metallothionein in carcinogenesis. , 1993, Cancer research.

[6]  Diponkar Banerjee,et al.  Metallothionein expression in patients with small cell carcinoma of the lung , 2001, Cancer.

[7]  E. Ioachim,et al.  Prognostic evaluation of metallothionein expression in human colorectal neoplasms. , 1999, Journal of clinical pathology.

[8]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[9]  Y. Hishikawa,et al.  Prognostic significance of the expressions of metallothionein, glutathione-S-transferase-pi, and P-glycoprotein in curatively resected gastric cancer. , 1997, Oncology.

[10]  K. Okuno,et al.  Gene expression analysis in colorectal cancer using practical DNA array filter , 2001, Diseases of the colon and rectum.

[11]  K. Schmid,et al.  Significance of metallothionein overexpression in human tumours , 1997, Histopathology.

[12]  A. Naganuma,et al.  Metallothionein induction prevents toxic side effects of cisplatin and adriamycin used in combination , 2004, Cancer Chemotherapy and Pharmacology.

[13]  C. Bosman,et al.  Superoxide dismutases in relation to the overall survival of colorectal cancer patients. , 1998, British Journal of Cancer.

[14]  C. Bosman,et al.  Superoxide dismutases in gastric and esophageal cancer and the prognostic impact in gastric cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  P. Edminson,et al.  Resistance against cis-dichlorodiammineplatinum in cultured cells with a high content of metallothionein. , 1981, Toxicology and applied pharmacology.

[16]  C. Borek.  Radiation and chemically induced transformation: free radicals, antioxidants and cancer. , 1987, The British journal of cancer. Supplement.

[17]  Simon C Watkins,et al.  Cytoplasmic metallothionein overexpression protects NIH 3T3 cells from tert-butyl hydroperoxide toxicity. , 1994, The Journal of biological chemistry.

[18]  B. Halliwell,et al.  Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. , 1996, The Biochemical journal.

[19]  P. Iversen,et al.  Tumor cell growth is inhibited by suppressing metallothionein-I synthesis. , 1997, Cancer letters.

[20]  L. Oberley,et al.  Role of superoxide dismutase in cancer: a review. , 1979, Cancer research.

[21]  H. Grindley,et al.  Differential effects on cell killing in metallothionein overexpressing CHO mutant cell lines. , 1990, Carcinogenesis.

[22]  J. Lancaster,et al.  Metallothionein protects against the cytotoxic and DNA-damaging effects of nitric oxide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Karin,et al.  Overexpressed human metallothionein IIA gene protects Chinese hamster ovary cells from killing by alkylating agents. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Horgan,et al.  Metallothionein expression in duct carcinoma in situ of the breast. , 1995, Human pathology.

[25]  J. Kägi.  Overview of metallothionein. , 1991, Methods in enzymology.

[26]  M. U. Mungan,et al.  Metallothionein expression in renal cell carcinoma: subcellular localization and prognostic significance. , 2001, The Journal of urology.

[27]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.

[28]  P. Moffatt,et al.  Metallothionein in physiological and physiopathological processes. , 1997, Drug metabolism reviews.

[29]  Ian O. Ellis,et al.  Metallothionein expression in human breast cancer , 1992 .

[30]  P. Isaacson,et al.  Immunoproliferative small-intestinal disease. An immunohistochemical study. , 1989, The American journal of surgical pathology.

[31]  U. Das,et al.  Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer. , 1990, Free radical biology & medicine.

[32]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[33]  K. Zedeler,et al.  Immunohistochemical detection of metallothionein in primary breast carcinomas and their axillary lymph node metastases. , 1994, Pathology, research and practice.

[34]  M. Webber,et al.  Metallothionein induction and deinduction in human prostatic carcinoma cells: relationship with resistance and sensitivity to adriamycin. , 1988, Cancer research.

[35]  P. Malfertheiner,et al.  Expression of metallothionein II in intestinal metaplasia, dysplasia, and gastric cancer. , 2000, Cancer research.

[36]  Oberley Td,et al.  Antioxidant enzyme levels in cancer. , 1997 .

[37]  Metallothionein expression prevents apoptosis: a study with antisense phosphorothioate oligodeoxynucleotides in a human T cell line. , 1998, Anticancer research.

[38]  A. Petkau.  Role of superoxide dismutase in modification of radiation injury. , 1987, The British journal of cancer. Supplement.

[39]  C. V. D. van de Velde,et al.  Metallothionein in human gastrointestinal cancer , 2000, The Journal of pathology.

[40]  B. Vallee,et al.  Cell cycle regulation of metallothionein in human colonic cancer cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[41]  C. V. D. van de Velde,et al.  Superoxide dismutases in the human colorectal cancer sequence , 1999, Journal of Cancer Research and Clinical Oncology.

[42]  T. Nakajima,et al.  Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis. , 1996, Oncology.

[43]  M. Volm,et al.  Expression of resistance-related proteins in tumoral and peritumoral tissues of patients with lung cancer. , 1996, Cancer letters.

[44]  Y. Hishikawa,et al.  Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus , 1999, British Journal of Cancer.

[45]  R. D'Incà,et al.  Immunohistochemical expression of metallothionein in normal human colorectal mucosa, in adenomas and in adenocarcinomas and their associated metastases , 1996, Histopathology.

[46]  D. Gill,et al.  A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis , 1997, Gene Therapy.

[47]  D. Hamer,et al.  Overexpression of metallothionein confers resistance to anticancer drugs. , 1988, Science.

[48]  S. Sahu.  Role of oxygen free radicals in the molecular mechanisms of carcinogenesis: A review∗ , 1991 .

[49]  D.,et al.  Regression Models and Life-Tables , 2022 .

[50]  A. Bakka,et al.  Increased resistance to chlorambucil in cultured cells with a high concentration of cytoplasmic metallothionein. , 1983, Cancer research.

[51]  J. Lazo,et al.  Enhanced apoptosis in metallothionein null cells. , 1997, Molecular pharmacology.

[52]  M. Becich,et al.  Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. , 1994, The Journal of urology.

[53]  J. Abel,et al.  Inhibition of hydroxyl-radical-generated DNA degradation by metallothionein. , 1989, Toxicology letters.

[54]  Metallothionein as an epithelial proliferative compartment marker for DNA flow cytometry. , 1993 .

[55]  菱川善隆.  Overexpression of Metallothionein Correlates with Chemoresistance to Cisplatin and Prognosis in Esophageal Cancer , 1997 .

[56]  N. Miura,et al.  Prevention of adverse effects of gamma-ray irradiation after metallothionein induction by bismuth subnitrate in mice. , 1989, European journal of cancer & clinical oncology.

[57]  J. Lazo,et al.  Role of metallothionein in carcinogenesis. , 1994, Toxicology and applied pharmacology.

[58]  R. Meneghini,et al.  Metallothionein protects DNA from oxidative damage. , 1993, The Biochemical journal.

[59]  H. Verspaget,et al.  Neoplasia-related changes of two copper (Cu)/zinc (Zn) proteins in the human colon. , 1990, Free radical biology & medicine.

[60]  S. Shibata,et al.  Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival , 1998, Cancer.

[61]  W. Böcker,et al.  Immunohistochemical metallothionein expression in colorectal adenocarcinoma: correlation with tumour stage and patient survival , 2004, Virchows Archiv.

[62]  R. Meneghini,et al.  V79 Chinese-hamster cells rendered resistant to high cadmium concentration also become resistant to oxidative stress. , 1988, The Biochemical journal.

[63]  Y. Hishikawa,et al.  Concurrent expressions of metallothionein, glutathione S-transferase-π, and P-glycoprotein in colorectal cancers , 2000, Diseases of the colon and rectum.

[64]  W. Böcker,et al.  Immunohistochemically demonstrated metallothionein expression in malignant melanoma , 1993, Histopathology.

[65]  L. Oberley,et al.  Antioxidant enzyme levels in cancer. , 1997, Histology and histopathology.